As a clinically common antitumor drug, crizotinib has optimal efficacy, low toxicity, and high safety, which can not only inhibit ROS1, EML4-ALK, and other signaling pathways but also suppress tumor cell growth and prevent tumor formation [17]. Here, ROS1 is linked to neoplasm.